US-based pharmaceutical company Eli Lilly and Company has announced a landmark investment of over $1 billion in India, marking one of the most significant foreign investments in the country’s healthcare manufacturing sector in recent times. This multi-year investment underscores India’s rising prominence as a global hub for innovation, research, and manufacturing in the pharmaceutical industry.
Union Minister of Commerce and Industry, Piyush Goyal, welcomed the announcement and highlighted India’s growing influence in the global business ecosystem. He noted that under Prime Minister Narendra Modi’s leadership, India has made significant strides in improving the ease of doing business, building global trust, and establishing itself as a preferred destination for high-value foreign investments.
Eli Lilly India plans to expand its contract manufacturing operations, increasing patient access to innovative medicines worldwide. The strategic investment will enhance the company’s manufacturing and supply chain capabilities to support its evolving global portfolio. Additionally, the firm intends to set up new Manufacturing and Quality facilities in Hyderabad, further bolstering the city’s position as a major life sciences and pharmaceutical hub.
The initiative is expected to generate thousands of employment opportunities for Telangana’s youth, strengthening the local workforce while boosting the regional economy. The announcement follows a meeting between Eli Lilly representatives and Telangana Chief Minister A. Revanth Reddy, along with Industries Minister D. Sridhar Babu, at the Integrated Command Control Centre.
This commitment comes just months after Eli Lilly inaugurated its Global Capability Centre (GCC) in Hyderabad in August, which aims to expand manufacturing capacity and global supply operations. The facilities will focus on critical therapeutic areas, including diabetes, obesity, cancer, Alzheimer’s disease, and autoimmune disorders.
Chief Minister Revanth Reddy praised Hyderabad as a global business city and reaffirmed the state government’s support for international investors. He expressed gratitude to Eli Lilly’s leadership for selecting Telangana for this expansion and assured comprehensive support for any future initiatives, reinforcing the state’s dedication to nurturing a favorable investment environment.
Eli Lilly’s $1 billion investment is set to strengthen India’s healthcare ecosystem, position Hyderabad as a leading global pharmaceutical hub, and foster long-term collaboration in life sciences innovation.
